Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Sold by Wetherby Asset Management Inc.

Wetherby Asset Management Inc. lessened its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,800 shares of the biopharmaceutical company’s stock after selling 307 shares during the quarter. Wetherby Asset Management Inc.’s holdings in Alexion Pharmaceuticals were worth $372,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cozad Asset Management Inc. purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter worth approximately $951,000. LS Investment Advisors LLC increased its stake in Alexion Pharmaceuticals by 5.2% during the 3rd quarter. LS Investment Advisors LLC now owns 7,056 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 349 shares in the last quarter. California Public Employees Retirement System increased its stake in Alexion Pharmaceuticals by 31.8% during the 3rd quarter. California Public Employees Retirement System now owns 469,855 shares of the biopharmaceutical company’s stock worth $46,018,000 after buying an additional 113,287 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Alexion Pharmaceuticals by 11.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 940,444 shares of the biopharmaceutical company’s stock worth $92,107,000 after buying an additional 98,196 shares in the last quarter. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Alexion Pharmaceuticals by 7.7% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 60,205 shares of the biopharmaceutical company’s stock worth $5,896,000 after buying an additional 4,309 shares in the last quarter. 94.68% of the stock is owned by institutional investors.

ALXN stock opened at $108.05 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.45. The business has a 50 day simple moving average of $102.36 and a 200-day simple moving average of $115.77. The firm has a market capitalization of $23.73 billion, a PE ratio of 15.24, a price-to-earnings-growth ratio of 1.02 and a beta of 1.65. Alexion Pharmaceuticals, Inc. has a 1 year low of $92.56 and a 1 year high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.32. The business had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.24 billion. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The business’s revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.02 earnings per share. On average, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 9.41 EPS for the current year.

Several research firms have commented on ALXN. JPMorgan Chase & Co. began coverage on Alexion Pharmaceuticals in a research note on Wednesday, July 31st. They set an “overweight” rating and a $172.00 price objective for the company. Citigroup set a $150.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 30th. William Blair began coverage on Alexion Pharmaceuticals in a research note on Thursday, September 26th. They set an “outperform” rating and a $146.00 price objective for the company. Stifel Nicolaus reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Friday, August 30th. Finally, Bank of America began coverage on Alexion Pharmaceuticals in a research note on Thursday, October 17th. They set a “buy” rating for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $159.00.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: Short Selling Stocks and Day Traders

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.